Eylea, which is used to treat age-related macular degeneration, brought in roughly $9.4 billion in sales last year, down a ...
Regeneron (NASDAQ:REGN) won a permanent injunction that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, ...
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...
Eylea is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. It is designed to block the growth of new blood vessels and decrease the ability of fluid to ...
EYLEA HD and EYLEA are administered by injection into the eye. You should not use EYLEA HD or EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of ...
agreed to review their AVTO6 treatment for eye disorders. The treatment could compete with Regeneron Pharmaceuticals’ (REGN) Eylea, which is widely used to treat diseases such as neovascular ...
blockbuster eye disease therapy, Eylea. A biologic named AVT06, Teva (NYSE:TEVA), and Alvotech’s (NASDAQ:ALVO) biosimilar, is backed by positive data from a clinical trial for patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results